

# New Products - Caprelsa

---

Caprelsa (**vandetanib**) is a tyrosine kinase inhibitor that inhibits vascular endothelial growth factor (VEGF)-stimulated VEGF receptor-2 tyrosine kinase. In addition, vandetanib inhibits epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase. Caprelsa is indicated for the treatment of patients with symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced or metastatic disease. It is contraindicated in patients with congenital long QT syndrome. Caprelsa is available as 100 mg and 300 mg tablets in blister packs of 30's.

*This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.*